Regeneron Pharmaceuticals, Inc. (REGN) Confident on Odronextamab Approval After Setbacks

We recently compiled a list of the 11 Cheap Biotech Stocks to Buy According to Hedge Funds. Regeneron Pharmaceuticals, Inc. is one of them.

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) tops our list for being one of the cheap biotech stocks to buy. It is a biotechnology company developing treatments for serious diseases, including eye conditions, inflammatory disorders, cancer, and rare diseases. Its strong R&D and antibody platform support long-term growth from drugs like Dupixent and new launches in oncology and respiratory care.

In Q2 2025, Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) reported strong results driven by Dupixent, which generated $4.34 billion in sales, exceeding expectations. However, Eylea sales declined 25%, and the FDA again declined approval for the blood cancer therapy odronextamab due to manufacturing issues at a third-party facility. The business remains confident that these issues can be resolved, as the drug is already approved in Europe and targets follicular lymphoma.

The company continues to emphasize innovation, awarding its 13th annual Regeneron Prize for Creative Innovation to early-career biomedical researchers and supporting global STEM education initiatives.

Looking ahead, Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)’s priorities include resolving regulatory challenges for odronextamab, expanding Dupixent’s market, and advancing new oncology and respiratory launches to sustain growth despite near-term setbacks.

While we acknowledge the potential of REGN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money.

Disclosure: None.